Alzamend Neuro (NASDAQ:ALZN) Trading Down 2.5% – Here’s What Happened

Posted by ABMN Staff on Jan 13th, 2026

Shares of Alzamend Neuro, Inc. (NASDAQ:ALZN – Get Free Report) fell 2.5% during mid-day trading on Monday . The stock traded as low as $2.20 and last traded at $2.33. 43,364 shares were traded during trading, a decline of 21% from the average session volume of 55,007 shares. The stock had previously closed at $2.39.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ALZN shares. Ascendiant Capital Markets lowered their target price on shares of Alzamend Neuro from $42.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, December 22nd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alzamend Neuro in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Alzamend Neuro has an average rating of “Hold” and an average price target of $28.00.

View Our Latest Stock Analysis on Alzamend Neuro

Alzamend Neuro Price Performance

The firm’s fifty day moving average price is $2.18 and its 200-day moving average price is $2.42. The company has a market cap of $8.85 million, a price-to-earnings ratio of -0.71 and a beta of -0.25.

Alzamend Neuro (NASDAQ:ALZN – Get Free Report) last released its quarterly earnings data on Tuesday, December 9th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.53. As a group, equities analysts forecast that Alzamend Neuro, Inc. will post -1.68 earnings per share for the current fiscal year.

About Alzamend Neuro

(Get Free Report)

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.